Prevalence and in vitro characteristics of reverse transcriptase (RT) N348I mutation in non-B subtypes, in the absence of viral load monitoring, in the DART Study (NORA substudy).
Prevalence and in vitro characteristics of reverse transcriptase (RT) N348I mutation in non-B subtypes, in the absence of viral load monitoring, in the DART Study (NORA substudy).
复制标题
DART 研究（NORA 子研究）中，在没有病毒载量监测的情况下，非 B 亚型中逆转录酶 (RT) N348I 突变的患病率和体外特征。
DOI：
--
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
D. Pillay
中科院分区：
文献类型：
--
作者：
A. McCormick;A. Burke;P. Katundu;F. Lyagoba;C. Parry;D. Yirrell;P. Munderi;V. Robertson;P. Kaleebu;D. Pillay
MRC Programme on AIDS/Uganda Virus Research Institute, Entebbe, Uganda: H Grosskurth, P Munderi, G Kabuye, D Nsibambi, R Kasirye, E Zalwango, M Nakazibwe, B Kikaire, G Nassuna, R Massa, K Fadhiru, M Namyalo, A Zalwango, L Generous, P Khauka, N Rutikarayo, W Nakahima, A Mugisha, J Todd, J Levin, A Ruberantwari, P Hughes, M Aber. Joint Clinical Research Centre, Kampala, Uganda: P Mugyenyi, C Kityo, D Tumukunde, F Ssali, D Atwine, G Mulindwa, R Byaruhanga, T Bakeimyaga-Grace, H Katabira, E Nimwesiga, G Barungi, S Atwiine, F Ahimbisibwe, S Tugume, T Otim, J Takubwa, M Mulindwa, S Murungi, J Tukamushaba, D Muebesa, H Kyomugisha, J Kagina, P Katundu, O Labeja. University of Zimbabwe, Harare, Zimbabwe: A Latif, J Hakim, V Robertson, A Reid, E Chidziva, A Jamu, S Makota, R Bulaya-Tembo, G Musoro, N Ngorima, F Taziwa, L Chakonza, H Chirairo, S Chitsungo, F Mapinge, A Mawora, C Muvirimi, G Tinago, J Chimanzi, J Machingura, C Maweni, S Mutsai, R Warara, M Matongo, S Mudzingwa, M Jangano, K Moyo, L Vere, M Phiri, Bafana T. Academic Alliance, Mulago Hospital, Uganda: E Katabira, J Oyugi, A Ronald, A Kambungu, R Nalumenya, F Sematala, R Nairubi, E Bulume, M Teopista, C Twijukye, Lubwana E. The AIDS Support Organisation (TASO), Uganda: A Coutinho, B Etukoit. Imperial College , London, UK: C Gilks, K Boocock, C Puddephatt, D Winogron. MRC Clinical Trials Unit, London, UK: J Darbyshire, DM Gibb, A Burke, D Bray, A Babiker, AS Walker, H Wilkes, M Rauchenberger, L Peto, K Taylor, M Spyer, A Ferrier, B Naidoo. Independent DART Trial Monitors: R Nanfuka, C Mufuka-Kapuya. Trial Steering Committee: I Weller (Chair), A Babiker (Trial Statistician), S Bahendeka, M Bassett, A Chogo Wapakhabulo, J Darbyshire, B Gazzard, C Gilks, H Grosskurth, J Hakim, A Latif, C Mapuchere, O Mugurungi, P Mugyenyi; Observers: C Burke, S Jones, C Newland, S Rahim, J Rooney, M Smith, W Snowden, J-M Steens. Data and Safety Monitoring Committee: A Breckenridge (Chair), A McLaren (Chair-deceased), C Hill, J Matenga, A Pozniak, D Serwadda. Endpoint Review Committee: T Peto (Chair), A Palfreeman, M Borok, E Katabira. Funding: DART is funded by the UK Medical Research Council, the UK Department for International Development (DFID), and the Rockefeller Foundation. GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided LPV/r (Kaletra/Aluvia) as part of the second-line regimen for DART. Virology Group: P Awio, A Burke, M Chirara, D Dunn, D Gibb, C Gilks, R Goodall, H Grosskurth, J Hakim, P Kaleebu, P Katundu, C Kityo, F Lyagoba, A McCormick, P Mugyenyi, P Munderi, N Ndembi, D Pillay, A Reid, V Robertson, S Tugume, D Yirrell. 1. N348I mutation was detectable in 10/71 patients failing first line HAART at 96wks on CBV plus ABC or NVP and was associated with NRTI and NNRTI resistant mutations. Prevalence and in vitro characteristics of Reverse Transcriptase (RT) N348I Mutation in Non-B subtypes, in the Absence of Viral Load Monitoring, in the DART Study (NORA substudy) A McCormick1 , A Burke2 , P Katundu3 , F Lyagoba4 , C Parry1 , D Yirrell5 , P Munderi4 , V Robertson6 , Pontiano Kaleebu4, D Pillay1 on behalf of the DART Virology Group. 1 UCL, London, UK; 2Med Res Council Clin Trials Unit, London, UK; 3Joint Clin Res Ctr, Kampala, Uganda; 4 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 5West of Scotland Spec Virology Ctr, Glasgow, UK; 6University of Zimbabwe, Harare. Poster #643 www.ctu.mrc.ac.uk/dart Email: adele.mccormick@ucl.ac.uk
